Champix®: The European Medicines Agency confirms a positive benefit-risk balance
2011.07.28
Active substance: varenicline
The benefits of Champix® as a smoking-cessation medicine outweigh the reported slight increase in cardiovascular events. The European Medicines Agency has confirmed that the benefit-risk balance for Champix® (varenicline) remains positive, despite the results of a recent meta-analysis on cardiovascular side effects of the medicinal product.
risk information - full text (available in German only)